C4 Therapeutics, Inc.
CCCC
$2.61
-$0.21-7.30%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -32.17M | -26.02M | -26.32M | -34.57M | -24.67M |
| Total Depreciation and Amortization | 460.00K | 615.00K | 456.00K | 480.00K | 442.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 16.53M | 6.10M | 6.40M | 8.74M | 9.09M |
| Change in Net Operating Assets | -16.03M | 7.25M | -13.82M | 7.42M | -9.00M |
| Cash from Operations | -31.21M | -12.06M | -33.29M | -17.93M | -24.13M |
| Capital Expenditure | -411.00K | -185.00K | -- | 4.00K | 13.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 4.50M | 39.11M | 29.13M | 13.67M | 149.00K |
| Cash from Investing | 4.09M | 38.92M | 29.13M | 13.67M | 162.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 7.63M | -- | -- | 111.00K | 10.29M |
| Repurchase of Common Stock | -24.00K | 0.00 | -155.00K | 0.00 | -85.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 164.00K | 0.00 | 109.00K | 1.00K | 297.00K |
| Cash from Financing | 7.77M | 0.00 | -46.00K | 112.00K | 10.51M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -19.35M | 26.86M | -4.21M | -4.15M | -13.47M |